Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93

M Colleoni; S Gelber; E Simoncini; O Pagani; RD Gelber; KN Price; M Castiglione-Gertsch; AS Coates; A Goldhirsch; B Thürlimann; M Castiglione; JP Collins; H Cortés Funes; M Green; A Hiltbrunner; SB Holmberg; DK Hossfeld; I Láng; J Lindtner; F Paganetti; CM Rudenstam; R Stahel; HJ Senn; A Veronesi; G Egli; M Rabaglio; R Studer; B Ruepp; R Maibach; E Marbot; M Strausak; R Gelber; B Cole; M Regan; D Zahrieh; Z Sun; J Bernhard; C Hürny; B Gusterson; G Viale; L Blacher; J Celano; M Isley; R Hinkle; S Lippert; K Scott; D Crivellari; S Monfardini; E Galligioni; MD Magri; A Buonadonna; S Massarut; C Rossi; E Candiani; A Carbone; R Volpe; M Roncadin; M Arcicasa; F Coran; S Morassut; G Marini; P Marpicati; M Braga; P Grigolato; L Lucini; G Martinelli; L Orlando; F Nolè; R Torrisi; T De Pas; F de Braud; S Cinieri; F Peccatori; A Luini; R Orecchia; G Renne; A Costa; S Zurrida; P Veronesi; V Sacchini; V Galimberti; M Intra; U Veronesi; A Ravaioli; D Tassinari; G Oliverio; F Barbanti; P Rinaldi; E Pini; G Drudi; M Antimi; M Minelli; V Bellini; R Porzio; E Pernazza; G Santeusanio; LG Spagnoli; S Foladore; L Foghin

Journal article

Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93

M Colleoni, S Gelber, E Simoncini, O Pagani, RD Gelber, KN Price, M Castiglione-Gertsch, AS Coates, A Goldhirsch, B Thürlimann, M Castiglione, JP Collins, H Cortés Funes, M Green, A Hiltbrunner, SB Holmberg, DK Hossfeld, I Láng, J Lindtner, F Paganetti Show all

Annals of Oncology | ELSEVIER | Published : 2007

DOI: 10.1093/annonc/mdm091

Abstract

Background: The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome. Patients and methods: From 1993 to 1999, IBCSG Trials 13-93 and 14-93 enrolled 2215 premenopausal and postmenopausal women with axillary node-positive, operable breast cancer. All patients received cyclophosphamide (Cytoxan, C) plus either doxorubicin (Adriamycin, A) or epirubicin (E) for four courses followed immediately (No Gap) or after a 16-week delay (Gap) by classical cyclophosphamide, methotrexate, and fluorouracil (CMF) for three courses. The median follow-up was 7.7 years. Results: The Ga..

View full abstract